Data from the company SPIRIT IV trial will XIENCE V to TAXUS at the Transcatheter Cardiovascular Therapeutics annual meeting in September 2009 werden.690 patients is the SPIRIT IV trial is one of the largest head – to-head randomized clinical trials between two drug – eluting stents and includes more than 1,000 patients with diabetes. Across the SPIRIT family of trials is planning Abbott about 22,000 patients with everolimus -eluting stents to study treat.
‘to the XIENCE PRIME stent is designed stent deliverability improving minimize vessel injury and provide easy access to lesions in complex anatomy. ‘.. ‘XIENCE PRIME superior outcomes superior outcomes from the extensive body of clinical evidence from the SPIRIT trials and offers design and system properties which system properties that reach it even easier appropriate for a doctor and treat making a lesion, ‘said Patrick Serruys, professor of interventional cardiology at the Thoraxcenter, Erasmus University Hospital, Rotterdam, The Netherlands. Read More